Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HEIDI J CRAYTON

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1669470720
CMS profile
74955
Location
VIENNA, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$212,367.02

357 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 4 of 8; records 151–200 of 357 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HEIDI J CRAYTON

NPI 1669470720 · CMS profile ID 74955

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

VIENNA, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 8; records 151–200 of 357 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1669470720?year=2025&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HEIDI J CRAYTON, NPI 1669470720, CMS profile ID 74955. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 8; records 151–200 of 357 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1669470720?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). HEIDI J CRAYTON, NPI 1669470720, CMS profile ID 74955. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 8; records 151–200 of 357 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1669470720?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
HEIDI J CRAYTON, NPI 1669470720, CMS profile ID 74955, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 8; records 151–200 of 357 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1669470720?year=2025&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

357 matching records · $212,367.02 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 357 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 357.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Vanda Pharmaceuticals Inc. $26.2707/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232957757 CMS
EMD Serono, Inc. $482.9207/17/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1236886792 CMS
EMD Serono, Inc. $361.1007/17/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1236888926 CMS
EMD Serono, Inc. $102.7907/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236889894 CMS
Biogen, Inc. $15.5107/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208303498 CMS
Biogen, Inc. $2.6507/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208426371 CMS
EMD Serono, Inc. $1,725.0007/14/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1236887002 CMS
EMD Serono, Inc. $21.0007/11/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1236874124 CMS
EMD Serono, Inc. $49.0007/11/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1236887560 CMS
EMD Serono, Inc. $8.1807/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236912419 CMS
EMD Serono, Inc. $81.9007/11/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1236912493 CMS
EMD Serono, Inc. $12.4907/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236868176 CMS
Biogen, Inc. $4,304.0007/09/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1208337721 CMS
Biogen, Inc. $97.6707/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208408806 CMS
Biogen, Inc. $159.0007/09/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1208476796 CMS
Celgene Corporation $18.3607/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184901111 CMS
EMD Serono, Inc. $3,795.0006/27/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1236886956 CMS
EMD Serono, Inc. $5,175.0006/27/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1236887216 CMS
EMD Serono, Inc. $6,555.0006/27/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1236923506 CMS
Vanda Pharmaceuticals Inc. $24.2006/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232957755 CMS
Celgene Corporation $5.7206/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184901109 CMS
Merck Healthcare KGaA $5,733.7506/23/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1234989038 CMS
Merck Healthcare KGaA $5,560.0006/23/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234989066 CMS
TG Therapeutics, Inc. $18.9306/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226256372 CMS
Novartis Pharmaceuticals Corporation $31.3606/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200009610 CMS
Biogen, Inc. $12.4706/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208391673 CMS
Biogen, Inc. $9.7506/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208494044 CMS
EMD Serono, Inc. $18.5706/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236922377 CMS
Vanda Pharmaceuticals Inc. $18.9906/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232957753 CMS
AstraZeneca Pharmaceuticals LP $19.6106/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206812979 CMS
Biogen, Inc. $25.3306/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208494034 CMS
TG Therapeutics, Inc. $4,387.5006/12/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226256444 CMS
TG Therapeutics, Inc. $123.5006/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226256452 CMS
TG Therapeutics, Inc. $219.6506/12/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226256482 CMS
TMS NeuroHealth Centers Inc. $28.0306/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1178990166 CMS
EMD Serono, Inc. $33.1506/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236875852 CMS
EMD Serono, Inc. $1,410.0106/10/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1236881983 CMS
EMD Serono, Inc. $110.8306/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236887570 CMS
EMD Serono, Inc. $326.8306/10/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1236888932 CMS
EMD Serono, Inc. $201.8406/10/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1236889010 CMS
EMD Serono, Inc. $204.0606/10/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1236889752 CMS
Celgene Corporation $16.5406/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184901103 CMS
EMD Serono, Inc. $123.0606/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236874290 CMS
EMD Serono, Inc. $899.2006/05/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1236923892 CMS
EMD Serono, Inc. $405.4106/05/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1236924092 CMS
EMD Serono, Inc. $234.8306/05/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1236924308 CMS
Amgen Inc. $30.0506/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228679707 CMS
Ares Trading SA $5,560.0006/04/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1234988990 CMS
Ares Trading SA $164.7306/04/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234988996 CMS
Ares Trading SA $362.1606/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1245736006 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $409,932.10 598
PY2020 $117,248.38 185
PY2021 $126,252.53 235
PY2022 $188,538.88 374
PY2023 $183,747.47 350
PY2024 $233,807.30 385
PY2025 $212,367.02 357

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $25,620.00 4
PY2025 Principal investigator $108,255.07 27
PY2024 Recipient $13,210.63 4
PY2024 Principal investigator $192,677.37 21
PY2023 Recipient $6,513.11 3
PY2023 Principal investigator $255,741.17 27
PY2022 Principal investigator $82,235.94 36
PY2021 Principal investigator $136,743.51 36
PY2020 Principal investigator $107,535.04 36
PY2019 Recipient $1,905.61 9
PY2019 Principal investigator $130,446.49 17

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

31 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Recipient GENZYME CORPORATION $10,282.05 12/22/2025 Covered Recipient Physician Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226093970
Principal investigator 1 TG Therapeutics, Inc. $6,800.00 11/30/2025 Non-covered Recipient Entity
MS Center of Greater Washington, PC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199589
Recipient GENZYME CORPORATION $6,705.75 11/17/2025 Covered Recipient Physician Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226093959
Recipient GENZYME CORPORATION $6,079.80 11/17/2025 Covered Recipient Physician Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226093963
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,647.00 10/09/2025 Non-covered Recipient Entity
MS CENTER OF GREATER WASHINGTON
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190313447
Principal investigator 1 Novartis Pharmaceuticals Corporation $170.78 10/08/2025 Non-covered Recipient Entity
MS CENTER OF GREATER WASHINGTON
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190313445
Principal investigator 1 TG Therapeutics, Inc. $1,300.00 09/30/2025 Non-covered Recipient Entity
MS Center of Greater Washington, PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199523
Principal investigator 1 TG Therapeutics, Inc. $20,100.00 09/30/2025 Non-covered Recipient Entity
MS Center of Greater Washington, PC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199539
Principal investigator 1 TG Therapeutics, Inc. $4,300.00 08/31/2025 Non-covered Recipient Entity
MS Center of Greater Washington, PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199521
Principal investigator 1 TG Therapeutics, Inc. $1,300.00 08/31/2025 Non-covered Recipient Entity
MS Center of Greater Washington, PC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199537
Recipient GENZYME CORPORATION $2,552.40 08/04/2025 Covered Recipient Physician Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226093953
Principal investigator 1 EMD Serono, Inc. $2,000.00 08/01/2025 Non-covered Recipient Entity
MS CENTER OF GREATER WASHINGTON PC
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240118431
Principal investigator 1 TG Therapeutics, Inc. $1,400.00 07/31/2025 Non-covered Recipient Entity
MS Center of Greater Washington, PC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199535
Principal investigator 1 TG Therapeutics, Inc. $2,401.74 07/14/2025 Non-covered Recipient Entity
MS Center of Greater Washington, PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199551
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
MS CENTER OF GREATER WASHINGTON PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211626506
Principal investigator 1 Roche Products Limited $164.50 06/25/2025 Non-covered Recipient Entity
MS CENTER OF GREATER WASHINGTON PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211626511
Principal investigator 1 TG Therapeutics, Inc. $1,200.00 06/01/2025 Non-covered Recipient Entity
MS Center of Greater Washington, PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199467
Principal investigator 1 TG Therapeutics, Inc. $1,425.00 06/01/2025 Non-covered Recipient Entity
MS Center of Greater Washington, PC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199479
Principal investigator 1 GENZYME CORPORATION $2,552.40 05/19/2025 Non-covered Recipient Entity
Heidi Crayton
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226089180
Principal investigator 1 TG Therapeutics, Inc. $3,800.00 05/01/2025 Non-covered Recipient Entity
MS Center of Greater Washington, PC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199477
Principal investigator 1 GENZYME CORPORATION $2,895.30 04/21/2025 Non-covered Recipient Entity
Heidi Crayton
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226089204
Principal investigator 1 TG Therapeutics, Inc. $3,550.00 03/31/2025 Non-covered Recipient Entity
MS Center of Greater Washington, PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199465
Principal investigator 1 TG Therapeutics, Inc. $200.00 03/31/2025 Non-covered Recipient Entity
MS Center of Greater Washington, PC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199475
Principal investigator 1 GENZYME CORPORATION $10,282.05 03/17/2025 Non-covered Recipient Entity
Heidi Crayton
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226089176
Principal investigator 1 TG Therapeutics, Inc. $5,900.00 02/28/2025 Non-covered Recipient Entity
MS Center of Greater Washington, PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199463
Principal investigator 1 TG Therapeutics, Inc. $2,134.88 02/03/2025 Non-covered Recipient Entity
MS CENTER OF GREATER WASHINGTON
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200051
Principal investigator 1 TG Therapeutics, Inc. $3,500.00 02/01/2025 Non-covered Recipient Entity
MS Center of Greater Washington, PC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199473
Principal investigator 1 EMD Serono, Inc. $400.00 01/27/2025 Non-covered Recipient Entity
MS CENTER OF GREATER WASHINGTON PC
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240118429
Principal investigator 1 Novartis Pharmaceuticals Corporation $14,520.98 01/14/2025 Non-covered Recipient Entity
MULTIPLE SCLEROSIS CENTER OF GREATER WASHINGTON
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190303231
Principal investigator 1 Novartis Pharmaceuticals Corporation $11,840.44 01/09/2025 Non-covered Recipient Entity
MS CENTER OF GREATER WASHINGTON
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190313449
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
MS CENTER OF GREATER WASHINGTON PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211626502